Anti-Viral Drugs Market Size, Driving Forces, Future Business and Forecast 2022 to 2032

BySanket Badgujar
Market Research

In 2022, the Anti-Viral Drugs Market is projected to be worth US$ 59,596.8 million. Throughout the projected period, growth will be impacted by the introduction of generic antiviral medications and growing public knowledge of the availability of various vaccinations for viral diseases. The entire demand for anti-viral medications is anticipated to reach around US$ 87,675.36 Million by 2032, growing at a CAGR of 3.9% between 2022 and 2032. Antiviral medications are prescribed specifically to treat viral infections. Similar to antibiotics, the majority of anti-viral medications are used to treat specific viral infections, whereas broad-spectrum anti-viral medications work against a variety of viruses. Antiviral medications prevent the growth of their intended pathogens rather than killing it.

Anti-viral drugs are medications that are specifically used to treat viral infections. Most anti-viral drugs, like antibiotics, are used to treat specific viral infections, whereas a broad-spectrum anti-viral drug is effective against a wide range of viruses. Antiviral drugs do not kill their target pathogens; instead, they inhibit their growth.

Request Sample Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-1951

The global anti-viral drugs market is expected to grow at a moderate rate in the pharmaceutical market due to increased awareness, an increase in diseased population, and the introduction of new drugs with improved efficacy. Some major patents are reaching their anti-viral medications expiry during forecast period, such as for Combivir, Sustiva, Tenofovir, Tamiflu, Relenza and Telbivudine. The patent expiries of these blockbuster drugs is expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive.

Late-stage pipeline drugs are expected to enter the market, positively affecting the market. Most antivirals are considered relatively harmless to the host and are thus used to treat infections. They differ from viricides, which are not medications but can destroy or deactivate virus particles both outside and inside the body.

Anti-viral drugs are used to treat patients with herpes viruses, HIV, influenza A and B viruses, and hepatitis B and C viruses.

Anti-viral Drugs Market: Drivers and Restraints

According to WHO, approximately 35.3 million people worldwide were infected with HIV as of October 2013. As a result, increased viral infection incidences are one of the key factors driving the growth of the anti-viral drugs market. Newer and more advanced treatments and formulations, such as vaccines, combination therapy, and others, are being introduced to the market as a result of the strong R&D activities.

As a result, one of the critical factors in the growth of the anti-viral drugs market is strong R&D. On the other hand, high failure risk, high R&D and therapy costs, and government austerity are some of the threats expected to stymie market growth.

These are some factors anticipated to fuel growth of global anti-viral drugs market within the forecast period of 2016-2026. However, increasing usage of natural products and high cost of developing drugs are the key challenges faced by the market.

Anti-viral Drugs Market: Overview

Didanosine, zidovudine, lamivudine, and stavudine currently dominate the generic market for anti-viral drugs. Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales drove the overall anti-viral drug market, accounting for more than half of the market share in 2010.

By the end of 2012, 9.7 million people in low- and middle-income countries were receiving antiretroviral therapy (ART). According to WHO, the number of patients on ART increased by 1.6 million in 2012, the largest increase in a single year.

Nearly four out of five people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.

Anti-viral Drugs Market: Regional Overview

Region wise, the global anti-viral drugs market is classified into regions namely, North America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, Middle East and Africa. According to WHO, in countries with Major ART scale-up such as Brazil or China, the death rate among people living with HIV has decreased by 80%. In 2015, in India the number of people living with HIV were 2.1 Mn and in U.S. the number was around 1.2 Mn in the year 2013.

Anti-viral Drugs Market: Key Players

Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.

Key Segments Covered in the Anti-Viral Drugs Industry Analysis

Anti-Viral Drugs Market by Product type:

  • Hepatitis-C antivirals
  • HIV antivirals
  • Herpes antivirals
  • Hepatitis-B antivirals
  • Influenza antivirals
  • Others (Pneumonia, Flu, etc.)

Anti-Viral Drugs Market by End-user:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers